Does Network Health Cover Metformin?

What Is Network Health and How Does Its Formulary Work?

Network Health is a Wisconsin-based health insurer offering commercial, Medicare Advantage, and marketplace plans primarily across northeastern and central Wisconsin. Like all U.S. insurers, it maintains a formulary (a list of covered drugs divided into cost tiers) that is updated annually. Generic drugs like metformin sit on Tier 1 or Tier 2 in the vast majority of commercial plans, meaning they carry the lowest cost-sharing obligation for members.

Formularies are filed with the Centers for Medicare and Medicaid Services (CMS) for Medicare Advantage plans and must comply with CMS Part D requirements [1]. On the commercial side, Network Health's formularies follow Wisconsin state insurance regulations overseen by the Office of the Commissioner of Insurance. The practical result: metformin generics almost always appear as a low-tier, low-cost option on formularies that include any oral diabetes agents at all.

To confirm your specific plan's coverage, the most reliable method is to log into your Network Health member portal, manage to "Drug Coverage," and search for "metformin hydrochloride." You can also call the member services number on the back of your insurance card. The formulary document itself is a public PDF, updated each plan year.

Metformin IR (immediate-release) and metformin ER (extended-release) are listed separately on some formularies. Generic metformin IR is almost universally covered. Generic metformin ER (also called metformin HCl ER or Glucophage XR generic) is covered on most plans but may sit one tier higher than IR on a small number of benefit designs [2].

Is Metformin FDA-Approved and What Diagnoses Trigger Coverage?

Metformin received FDA approval for Type 2 diabetes mellitus in 1994 and remains one of the most prescribed medications in the United States [3]. The FDA label covers adults and children age 10 and older. Coverage under any insurance plan, including Network Health, is straightforward when the prescription carries an ICD-10 diagnosis code for Type 2 diabetes (E11.x) or prediabetes-related conditions where metformin is guideline-supported.

The American Diabetes Association's 2024 Standards of Care state: "Metformin remains a cost-effective medication for the management of type 2 diabetes and should be considered as background therapy" [4]. This guideline backing means that when a prescriber submits a claim for metformin with an E11 code, insurers including Network Health almost never require prior authorization.

Prediabetes (ICD-10 R73.09) is a grayer area. The American Diabetes Association does recommend metformin for high-risk prediabetes patients, particularly those with BMI <35, age <60, and prior gestational diabetes [4]. Some Network Health plans cover this indication; others may require a step through lifestyle intervention documentation first. Checking the plan's coverage criteria document or submitting a prior authorization request with clinical notes solves this quickly.

The FDA also approved metformin for polycystic ovary syndrome (PCOS) management, though technically this remains off-label [5]. Network Health coverage for PCOS-related metformin prescriptions varies by plan and typically requires the prescriber to document the clinical rationale.

Coverage for Off-Label Longevity Use: What to Expect

Metformin's potential as a longevity drug has attracted significant research attention, driven in large part by observational data and the ongoing NIH-funded TAME (Targeting Aging with Metformin) trial, which is enrolling approximately 3,000 adults aged 65, 79 at 14 U.S. sites to evaluate metformin 1 to 500 mg/day against age-related disease onset [6]. Despite this scientific interest, metformin is not FDA-approved for longevity or anti-aging indications as of 2025.

Insurance plans, Network Health included, do not reimburse drugs for non-approved indications unless a coverage policy explicitly lists the condition. Because "aging" is not a recognized ICD-10 diagnosis category eligible for pharmaceutical reimbursement under CMS guidelines, prescriptions written solely for longevity will be denied at adjudication. The pharmacy claim requires a billable diagnosis code, and no current ICD-10 code maps to "longevity optimization."

The practical workaround many clinicians use: if the patient also has prediabetes, insulin resistance, or metabolic syndrome (ICD-10 E88.81), the prescription can legitimately carry one of those codes and may be covered. This is not a documentation trick. It reflects the reality that patients seeking metformin for longevity reasons often do have metabolic comorbidities that independently qualify for coverage. A 2022 analysis in JAMA Network Open found that approximately 96 million American adults had prediabetes, the majority undiagnosed [7]. Many longevity-focused patients fall into this population.

Without a covered diagnosis, metformin is still inexpensive. Generic metformin IR 500 mg #60 tablets costs approximately $4, $10 at Walmart, Costco, and many pharmacy chains without insurance. The affordability makes it unusual among longevity-focused drugs in that the out-of-pocket cost barrier is low even without insurance coverage.

Metformin Dosing, Formulations, and Which Version Network Health Covers

Standard dosing for Type 2 diabetes begins at 500 mg twice daily with meals, titrated up to a maximum of 2 to 550 mg/day in divided doses, per the FDA prescribing information [3]. The TAME trial uses 1 to 500 mg/day as the longevity protocol dose, split as 500 mg three times daily [6].

Network Health formularies generally cover:

• Metformin HCl IR tablets (500 mg, 850 mg, 1 to 000 mg): Tier 1 generic on nearly all plans
• Metformin HCl ER tablets (500 mg, 750 mg, 1 to 000 mg): Tier 1 or Tier 2 generic depending on plan year
• Osmotic ER formulation (Glumetza generic): may be Tier 2 or Tier 3 on some plans; check formulary
• Metformin oral solution (Riomet ER): brand-name; higher tier and may require PA

The brand-name Glucophage is rarely covered under commercial plans when a bioequivalent generic exists. CMS Part D rules require plans to cover at least two drugs per therapeutic class, but generic substitution is standard [1]. If your pharmacy dispenses brand-name Glucophage when a generic is available, the plan will typically pay the generic rate and you pay the brand-minus-generic difference.

Metformin ER formulations are clinically preferred by some patients and prescribers because gastrointestinal side effects (nausea, diarrhea) are less common with ER. A randomized trial of 179 patients found that metformin ER produced significantly lower rates of gastrointestinal adverse events compared with IR at equivalent doses [8]. If ER sits on a higher tier for your plan, your prescriber may submit a formulary exception request citing tolerability data.

Prior Authorization, Step Therapy, and Exceptions

Prior authorization (PA) for metformin is rare when the indication is Type 2 diabetes. Network Health, like most insurers, places generic Tier 1 generics on its "no PA required" list for first-line diabetes medications, consistent with CMS guidance that step therapy should not delay proven first-line agents [9].

Step therapy may apply in some commercial plan designs for ER formulations: the plan requires a trial of IR first before covering ER. If IR causes intolerable GI effects, your prescriber can request a step therapy exception by documenting the adverse reaction. Most insurers, including Network Health, must respond to standard PA and exception requests within 72 hours (or 24 hours for urgent requests) under state and federal law [10].

To submit a PA or exception request:

1. Your prescriber completes Network Health's prior authorization form (available on the provider portal at networkhealth.com).
2. Clinical notes documenting the diagnosis, prior treatment attempts, and reason for the requested drug are attached.
3. Network Health's pharmacy benefit team reviews the submission, typically within 1, 3 business days.

If PA is denied, the first appeal goes to Network Health's internal utilization management review. If that is denied, Wisconsin residents have the right to an external independent review through the Wisconsin Office of the Commissioner of Insurance [10]. CMS requires Medicare Advantage plans to follow the Part D coverage determination and appeals process, with specific timelines defined in 42 CFR Part 423 [1].

What Metformin Actually Costs Without Insurance

Cost is rarely a barrier for metformin specifically, which is one reason it remains so widely prescribed. Across major U.S. pharmacy chains and discount programs, the cash prices are:

• Walmart $4 program: metformin IR 500 mg #30 for $4; #90 for $10
• GoodRx coupon price: metformin IR 500 mg #60 typically $4, $8 depending on pharmacy
• Mark Cuban's Cost Plus Drugs (costplusdrugs.com): metformin 500 mg #90 listed at approximately $5, $7 as of 2024
• Costco pharmacy: metformin ER 500 mg #90 typically under $15

These prices reflect the fact that metformin went off-patent in 2002 and is manufactured by dozens of generic producers [3]. For most patients, the question of whether Network Health covers metformin matters financially only if they are obtaining it in very large quantities (90-day supplies) or using a brand-name or specialty formulation.

The Inflation Reduction Act of 2022 capped out-of-pocket costs for insulin under Medicare Part D but did not impose a specific cap on metformin [11]. Metformin's existing low cost made a specific cap unnecessary.

How Metformin Compares to Other Diabetes Drugs in Network Health's Formulary

Understanding metformin's tier placement in context helps clarify why coverage disputes are uncommon for this drug compared to newer agents.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) typically sit on Tier 3 or Tier 4 specialty tiers and frequently require prior authorization even for approved Type 2 diabetes indications, with monthly costs exceeding $900 without insurance [12]. SGLT2 inhibitors (empagliflozin, dapagliflozin) are usually Tier 3, with copays of $40, $75 per month under commercial plans. DPP-4 inhibitors (sitagliptin) remain brand-dominant and typically Tier 3.

Metformin, by contrast, is the only oral diabetes first-line agent with consistent Tier 1 placement across virtually all commercial formularies. The ADA's 2024 Standards note that cost-effectiveness analyses continue to favor metformin as background therapy precisely because of this favorable cost profile [4].

A 2020 meta-analysis published in Diabetes Care (which analyzed 17 randomized trials covering 10,680 patients) confirmed that metformin reduced HbA1c by a mean of 1.12% compared with placebo, consistent with three decades of clinical use [13]. The UKPDS 34 trial (N=1,704) established metformin's cardiovascular safety advantage in overweight patients with Type 2 diabetes, showing a 39% reduction in myocardial infarction risk compared to conventional therapy, a finding that has not been replicated by all newer agents despite higher costs [14].

Metformin and the Longevity Science Behind the Coverage Gap

The gap between metformin's scientific longevity profile and its insurance coverage status is worth examining directly. Several observational studies suggest that diabetic patients on metformin outlive non-diabetic controls not taking metformin, a paradox that drove the design of the TAME trial [15].

A 2014 observational study published in Diabetes, Obesity and Metabolism (N=78,241 matched patients) found that metformin-treated Type 2 diabetics had longer survival than matched non-diabetic controls, a counterintuitive result that prompted substantial mechanistic investigation [15]. Metformin activates AMPK (AMP-activated protein kinase), inhibits mTORC1, reduces mitochondrial complex I activity, and modulates the gut microbiome, all pathways with theoretical relevance to aging biology [16].

The National Institute on Aging is funding the TAME trial with a $75 million commitment, the first time a federal agency has funded a clinical trial specifically designed to target the aging process as a unifying biological endpoint [6]. TAME's primary composite outcome covers time to first occurrence of myocardial infarction, stroke, heart failure, cancer, dementia, or death. Results are expected between 2026 and 2028.

Insurance coverage will not change until FDA approves a new indication. The FDA has signaled openness to reviewing aging as a disease endpoint if TAME provides sufficient evidence, but no NDA for a longevity indication has been submitted as of 2025 [17]. Until that regulatory step occurs, longevity-focused prescriptions remain outside the covered benefit for Network Health and every other U.S. insurer.

Checking Your Specific Network Health Plan

The steps below apply regardless of which Network Health plan design you have.

Step 1. Log into your Network Health member portal. Manage to "Benefits and Coverage" and then "Drug Coverage (Formulary)."

Step 2. Search for "metformin hydrochloride" and select your dosage strength and formulation (IR vs. ER). The formulary lookup will display the tier, copay, and any utilization management requirements.

Step 3. Compare your plan year formulary. Network Health updates formularies on January 1 each year. A drug that was Tier 1 in 2024 may have moved to Tier 2 in 2025 if the plan renegotiated its pharmacy benefit manager contract.

Step 4. If you see a prior authorization flag, ask your prescriber to submit supporting documentation preemptively rather than waiting for a pharmacy denial.

Step 5. If your plan does not cover metformin for your diagnosis, ask your prescriber about diagnosis coding review or submit a formulary exception. CMS Part D plans must provide a coverage determination within 72 hours of a standard request [1].

Kidney Function, Contraindications, and Coverage of Alternatives

Metformin carries an FDA black box warning regarding lactic acidosis risk in patients with renal impairment [3]. The FDA updated its labeling in 2016 to allow use in patients with eGFR >30 mL/min/1.73m² (previously contraindicated below eGFR 60) [18]. Patients with eGFR <30 cannot use metformin and will need an alternative agent.

For patients who are contraindicated for metformin, the coverage calculus shifts significantly. SGLT2 inhibitors or GLP-1 receptor agonists become first-line alternatives in CKD patients with Type 2 diabetes per the 2022 ADA/KDIGO consensus report [19]. These drugs sit on higher formulary tiers and almost always require prior authorization, making the insurance question much more consequential.

Network Health Medicare Advantage plans follow CMS Part D formulary exception rules, which require coverage of a non-formulary drug if the formulary alternatives are contraindicated or have caused adverse effects [1]. This is the regulatory pathway for obtaining coverage of a higher-tier diabetes agent when metformin is contraindicated due to renal insufficiency.